Healthcare Services company Thyrocare Technologies announced Q4FY25 results Consolidated revenue: Rs 187.2 crore compared to Rs 154.2 crore during Q4FY24, change 21% YoY with Pathology and Radiology segments growing by 23% YoY and 7% YoY respectively. PAT: Rs 21.3 crore compared to Rs 17.2 crore during Q4FY24, change 24%. Reported EBITDA: Rs 57.4 crore compared to Rs 33.8 crore during Q4FY24, change 70%. Total volume in FY25 grew to 167.9 million, largest by far on volume. Revenue from franchise surged by 22% YoY, and partnership revenue saw 24% YoY growth. Consolidated gross margin stood at 74%, and normalized EBITDA margin was 35%. Standalone normalized EBITDA grew by 72% YoY, while PAT* increased by 72% YoY. Consolidated normalized EBITDA grew by 78% YoY, while PAT* increased by 88% YoY. Recommended a final dividend of Rs 21 per equity share subject to the approval of shareholders at the ensuing shareholders meeting. Consolidated cash reserves as of March 2025 is Rs 191.8 crore. Opened new labs in Bhagalpur and Kashmir. Result PDF